Health·August 6, 2026·2 min read

FDA Approves First mRNA Flu Shot From Moderna For Adults 50+

Traditional OK for 50–64, accelerated nod for 65+ ahead of 2026–27 season

Logo of the U.S. Food and Drug Administration (FDA).
File photoLogo of the U.S. Food and Drug Administration (FDA).U.S. Food and Drug Administration

The U.S. Food and Drug Administration on August 5, 2026 approved Moderna’s mFLUSIVA (mRNA-1010), the first messenger RNA–based seasonal influenza vaccine cleared for use in the United States. The FDA granted traditional approval for adults 50–64 and accelerated approval for adults 65+, positioning doses to be available for the 2026–2027 flu season.

The decision follows a unanimous 9–0 vote on June 18, 2026 by the FDA’s Vaccines and Related Biological Products Advisory Committee recommending that benefits outweigh risks in both age groups. Moderna’s filing was underpinned by a Phase 3 efficacy trial (P304) enrolling 40,805 adults across 11 countries, which showed a 26.6% higher relative vaccine efficacy against protocol-defined, RT-PCR–confirmed influenza-like illness versus a licensed standard-dose comparator in adults 50+. For those 65+, the FDA used the accelerated pathway based on immunogenicity data indicating stronger antibody responses than a conventional high-dose flu vaccine, with a required post-marketing confirmatory study to verify clinical benefit.

The approval marks the first U.S. seasonal influenza vaccine built on mRNA technology. Regulators said the platform could allow manufacturers to update vaccines more quickly as influenza strains evolve and reduce reliance on traditional egg-based production methods. Moderna expects doses to be available in time for routine fall vaccination while the required confirmatory study in older adults continues.

After the FDA initially declined to review the application in February 2026 because of questions surrounding the trial comparator for older adults, the agency accepted a revised submission and advanced the vaccine to advisory committee review ahead of this week's approval. The separate approval pathways reflect the FDA’s determination that additional clinical evidence is still needed to confirm effectiveness in adults 65+, even as the vaccine becomes available for the 2026–2027 flu season.

Community discussion
"How should providers prioritize mFLUSIVA versus existing high-dose or adjuvanted flu vaccines for adults 65+ while the confirmatory study is underway?"